πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11219614

Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

Galera Labs, LLC Β· Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11213592

Antibody-sting agonist conjugates and their use in immunotherapy

The Board of Regents of the University of Texas System Β· Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11213514

Alpha-1-adrenergic receptor agonist therapy

The Regents of the University of California Β· Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11207339

Targeted cancer therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11207322

Method and composition related to combination therapy for addiction

The Board of Regents of the University of Texas System Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11202803

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11202804

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11197932

Polymer-drug conjugates for combination anticancer therapy

The Regents of the University of California Β· Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11192958

Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease

The Board of Regents of the University of Texas System Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11185585

Methods and compositions for improving antiangiogenic therapy with anti-integrins

The Regents of the University of California Β· Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11168303

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11168304

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11168142

Administration of kynurenine depleting enzymes for tumor therapy

The Board of Regents of the University of Texas System Β· Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11166936

Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

Auransa Inc. Β· Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11160779

Methods of providing solriamfetol therapy to subjects with impaired renal function

Jazz Pharmaceuticals Ireland Limited Β· Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11154574

Tumor infiltrating lymphocytes and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11147837

Modified cells and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11129908

Gene therapy vectors for treating heart disease

Tenaya Therapeutics, Inc. Β· Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11118186

Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and

The Board of Regents of the University of Texas System Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11116838

Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy

Inovio Pharmaceuticals, Inc. Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11090344

Adenovirus and immunomodulator combination therapy

The Board of Regents of the University of Texas System Β· Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11090290

Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting

Monopar Therapeutics Inc. Β· Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11091555

Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 che

Five Prime Therapeutics, Inc. Β· Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11083737

Methods of administering deflazacort therapy

PTC THERAPEUTICS, INC. Β· Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted